5-HT3 antagonists reduce morphine self-administration in rats

Area of Science:

• Pharmacology
• Neuroscience
• Addiction Research

Background:

• Opioid dependence remains a significant public health challenge.
• Understanding the neurobiological mechanisms underlying opioid intake is crucial for developing effective treatments.
• 5-HT3 receptor antagonists have shown promise in modulating various substance use behaviors.

Purpose of the Study:

• To investigate the effects of ondansetron and tropisetron on morphine consumption in naive and morphine-dependent rats.
• To determine if these 5-HT3 receptor antagonists can reduce both acute and long-term morphine intake.
• To assess the potential of these compounds in mitigating relapse behaviors after detoxification.

Main Methods:

• Rats were administered ondansetron or tropisetron prior to and during a 21-day period of morphine availability in sucrose solution.
• Different dosages and administration timings of the antagonists were tested.
• Following chronic morphine exposure, rats underwent a detoxification period and were then given a choice between sucrose and morphine to assess relapse-related intake.
• Cyproheptadine was used as a control substance.

Main Results:

• Pre-treatment and concurrent administration of ondansetron (1 microgram/kg) significantly reduced morphine intake starting from day 9.
• Higher doses of ondansetron and tropisetron (1 microgram/kg) also reduced morphine consumption.
• Rats treated with ondansetron or tropisetron showed reduced morphine intake during the free-choice period after detoxification compared to controls.
• Cyproheptadine did not affect morphine intake.

Conclusions:

• Ondansetron and tropisetron effectively reduce morphine intake in both naive and morphine-dependent rats.
• These 5-HT3 receptor antagonists demonstrate potential as therapeutic agents for managing opioid consumption and dependence.
• The findings support the role of the 5-HT3 receptor in modulating opioid reward and intake behaviors.